GSTM1 and myeloid neoplasm: Other reimbursable cases are those receiving chemotherapy for non-myeloid malignancies; patients with Hb ≤ 10 g/dL, serum ferritin < 100 ng/mL, or TSAT < 20%; patients who are unresponsive to erythropoietin treatment for CKD or non-myeloid malignancies, with serum ferritin < 300 ng/mL or TSAT < 30% and with Hb ≤ 11 g/dL for CKD patients on dialysis and Hb ≤ 10 g/dL for patients on chemotherapy with non-myeloid malignancies.